Mallinckrodt Pharmaceuticals (MNK) To Present Data For Investigational And Approved Extended-Release Opioid Combination Medicines At PAINWeek
8/28/2014 10:44:02 AM
ST. LOUIS--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today announced that clinical data for its investigational opioid, MNK-155 (hydrocodone bitartrate and acetaminophen) and approved opioid combination product XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) will be presented at PAINWeek 2014, a national conference on pain for frontline practitioners, September 2-6, in Las Vegas, Nevada.
MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen being studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. MNK-155 is formulated with both immediate- and extended-release components. The NDA for MNK-155 was accepted for review by the U.S. Food and Drug Administration (FDA) in May 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by